How Does Canopy Growth Make its Money?
Canopy Growth is one of the most widely followed cannabis companies in the world, having been the first North American cannabis company to list on the New York Stock Exchange. The company operates in the Canadian adult-use and medical cannabis markets, and has been restructuring aggressively to survive after burning through billions in cash since legalization. Canopy made headlines with a $4 billion investment from Constellation Brands (maker of Corona beer) in 2018 — the largest corporate bet on cannabis ever — though the investment has lost significant value. The company has pivoted its US strategy through a complex arrangement with Canopy USA, which holds options on US cannabis companies (Acreage Holdings, Wana Brands, Jetty Extracts) that would be exercised if US federal legalization occurs.
Canopy Growth (CGC) Business Model
Canopy Growth operates in the cannabis sector. Below is a summary of Canopy Growth’s revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from Canopy Growth’s 2024 fiscal year filings with the SEC.
Canopy Growth Competitors
Canopy Growth’s key competitors and comparable public companies in the cannabis sector include Tilray Brands, Constellation Brands, Pfizer, and Anheuser Busch Inbev. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Canopy Growth stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Canada Cannabis (Adult-Use & Medical) | $250 | $270 | -7.4% |
| International (Medical Cannabis, Germany) | $40 | $35 | +14.3% |
| Storz & Bickel (Vaporizers) | $60 | $55 | +9.1% |
| This Works (Wellness) | $15 | $15 | +0.0% |
| Total Revenue | $350 | $380 | -7.9% |
Canada Cannabis (Adult-Use & Medical) — 71% of Revenue
International (Medical Cannabis, Germany) — 11% of Revenue
Storz & Bickel (Vaporizers) — 17% of Revenue
This Works (Wellness) — 4% of Revenue
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $350 | $380 |
| Cost of Revenue | $280 | $310 |
| Gross Profit | $70 | $70 |
| Operating Expenses | $250 | $350 |
| Operating Income | $-180 | $-280 |
| Net Income | $-300 | $-600 |
All values in millions USD unless otherwise stated.
Key Financial Metrics
- Gross Margin: 20.0%
- Operating Margin: -51.4%
- Revenue Growth: -7.9%
Is Canopy Growth Profitable?
Canopy Growth (CGC) profitability depends on the reporting period and business cycle. Review the income statement above for the latest figures.
What to Watch
- US federal legalization or rescheduling — existential catalyst for the stock
- Cost restructuring progress and path to positive free cash flow
- Canopy USA structure and readiness to acquire US cannabis assets on legalization
- Cash runway and potential need for further dilutive capital raises
Canopy Growth (CGC) Financial Summary
Canopy Growth (CGC) is a cannabis company that generated $350 in total revenue in fiscal year 2024. Revenue grew -7.9% year-over-year. For a deeper look at Canopy Growth’s revenue breakdown, business segments, and financial performance, review the detailed analysis above.